Inventprise

IN THE PRESS

Drug Development

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

January 2, 2024

·

4 min read

Drug Development

New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation

November 10, 2022

·

3 min read

Business

Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines

May 10, 2022

·

3 min read

BioForest

Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials

November 10, 2021

·

3 min read

JOBS